Supported by Health Professionals Bank. The results of this survey equips APNA members with information on the workforce conditions of your profession, and helps APNA’s develop evidence-based policy and programs relating to the primary health care nurse workforce and to advocate for you.
Know Meningoccal: Everything from A to Y - Dr Julianne Bayliss
A workshop at the APNA 2018 National Conference - Nurseforce for the Future - Know Meningoccal: Everything from A to Y with Dr Julianne Bayliss.
Invasive meningococcal disease (IMD) is a rare but deadly bacterial infection most commonly presenting as sepsis or meningitis. In Australia, cases of IMD have been steadily increasing over the last five years (2013-2017), with 2017 recording the highest number of cases seen since 2006.
Recent changes in disease epidemiology has seen a rise in serogroup W, with a doubling of cases attributable to the W serogroup from 2013 to 2014, and a trebling of cases between 2015-2016.
Meanwhile, notifications of serogroup Y IMD have also increased, and serogroup B disease has not abated. To add to the complexity, there are state-to-state differences for the most prevalent serogroups causing disease.
Vaccination is an important way health care providers can help to protect patients against IMD. Several meningococcal vaccines exist to help protect against the serogroups common to Australia. However, not all of these vaccines are available on the National Immunisation Program, or State Funded Programs. In this session, Dr Julianne Bayliss explores the recent epidemiological trends, the funded vaccination programs in place, and vaccine recommendations outside of these funded programs.